255 related articles for article (PubMed ID: 24615887)
1. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Patel JJ; Butters OR; Arnett TR
Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
[TBL] [Abstract][Full Text] [Related]
2. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone.
Bruedigam C; Eijken M; Koedam M; van de Peppel J; Drabek K; Chiba H; van Leeuwen JP
Stem Cells; 2010 May; 28(5):916-27. PubMed ID: 20213769
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation.
Weivoda MM; Hohl RJ
Bone; 2012 Feb; 50(2):467-76. PubMed ID: 22019459
[TBL] [Abstract][Full Text] [Related]
5. PPAR agonists modulate human osteoclast formation and activity in vitro.
Chan BY; Gartland A; Wilson PJ; Buckley KA; Dillon JP; Fraser WD; Gallagher JA
Bone; 2007 Jan; 40(1):149-59. PubMed ID: 17010686
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
7. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.
Cho ES; Kim MK; Son YO; Lee KS; Park SM; Lee JC
Mol Cells; 2012 Feb; 33(2):173-81. PubMed ID: 22286232
[TBL] [Abstract][Full Text] [Related]
8. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).
Sottile V; Seuwen K; Kneissel M
Calcif Tissue Int; 2004 Oct; 75(4):329-37. PubMed ID: 15549648
[TBL] [Abstract][Full Text] [Related]
9. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Okamoto H; Iwamoto T; Kotake S; Momohara S; Yamanaka H; Kamatani N
Clin Exp Rheumatol; 2005; 23(3):323-30. PubMed ID: 15971419
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.
Takano M; Otsuka F; Matsumoto Y; Inagaki K; Takeda M; Nakamura E; Tsukamoto N; Miyoshi T; Sada KE; Makino H
Mol Cell Endocrinol; 2012 Jan; 348(1):224-32. PubMed ID: 21888945
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
13. Icariin influences adipogenic differentiation of stem cells affected by osteoblast-osteoclast co-culture and clinical research adipogenic.
Zhang S; Feng P; Mo G; Li D; Li Y; Mo L; Yang Z; Liang D
Biomed Pharmacother; 2017 Apr; 88():436-442. PubMed ID: 28122309
[TBL] [Abstract][Full Text] [Related]
14. The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Pruimboom-Brees IM; Francone O; Pettersen JC; Kerlin RL; Will Y; Amacher DE; Boucher GG; Morton D
Toxicol Pathol; 2012 Jul; 40(5):810-8. PubMed ID: 22504321
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors increase human sebum production.
Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.
Ovcharenko E; Hansen MK; Goltsman I; Abu-Saleh N; Abassi Z; Walsh K; Miele G; Feuerstein GZ; Winaver J
Nephron Physiol; 2010; 115(3):p21-30. PubMed ID: 20460939
[TBL] [Abstract][Full Text] [Related]
18. Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats.
Aguirre JI; Leal ME; Rivera MF; Vanegas SM; Jorgensen M; Wronski TJ
J Bone Miner Res; 2007 Jun; 22(6):877-88. PubMed ID: 17352655
[TBL] [Abstract][Full Text] [Related]
19. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways.
Mei CL; He P; Cheng B; Liu W; Wang YF; Wan JJ
Cell Biol Int; 2009 Mar; 33(3):301-8. PubMed ID: 19114110
[TBL] [Abstract][Full Text] [Related]
20. 1α,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization.
Woeckel VJ; Bruedigam C; Koedam M; Chiba H; van der Eerden BC; van Leeuwen JP
Gene; 2013 Jan; 512(2):438-43. PubMed ID: 22967709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
